COMPASS THERAPEUTICS, INC. Deferred State and Local Income Tax Expense (Benefit)
COMPASS THERAPEUTICS, INC. (CMPX) reported Deferred State and Local Income Tax Expense (Benefit) of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-18.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2022-03-18
- COMPASS THERAPEUTICS, INC. deferred state and local income tax expense (benefit) for fiscal 2021 was $0.00.
- COMPASS THERAPEUTICS, INC. deferred state and local income tax expense (benefit) for fiscal 2020 was $0.00.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-18 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |